SAN DIEGO (PRWEB) February 27, 2018 -- Integral membrane proteins (IMP) are difficult to extract from membranes and are characteristically unstable, making this target class challenging to study. Biosensor surface chemistries often need to be customized for the unique requirements of each IMP, necessitating extensive assay development. Nanomedical Diagnostics, a leading manufacturer of graphene biosensors that accelerate pharmaceutical and biotherapeutic development, launches the new Hydrophobic-Immobilization Biosensor – FLEX, for use with the company’s Agile R100 label-free personal assay system. The new biosensor enables rapid surface chemistry customization, reducing the time required for IMP researchers to gain reliable in vitro kinetic data.
“The FLEX biosensor provides a flat, highly-uniform hydrophobic surface that provides the ability to quickly immobilize membrane fractions without the need for time-consuming and potentially error-prone linker chemistry,” says Nanomedical Diagnostics CEO, Ross Bundy. “Native proteins can be analyzed without extensive modification, as the FLEX biosensor eliminates the need for tags or labels. This provides for unprecedented assay flexibility with the ability to immobilize any protein, membrane fraction, or lipid monolayer.”
The new biosensor, combined with the Agile R100 kinetic characterization platform which has low sample and material requirements, makes it easy to study even tiny amounts of target protein. The unprecedented uniformity of the hydrophobic surface increases data reliability, and elimination of the need to tag or label greatly reduces protein engineering requirements, allowing difficult IMPs to be studied closer to their native state. Like all Agile R100 biosensors, the FLEX chip is regeneration-capable and highly cost-effective. Agile R100’s single-sample format lets researchers apply sample directly to the sensor surface, reducing protein degradation.
“In addition to providing a convenient way to study IMPs, the new FLEX chip enables rapid assay development for cell-based assays, including whole-cell assays. The uniform hydrophobic surface allows for amenable growth conditions in which to apply whole cells, so researchers don’t need to work around challenging surface chemistries to immobilize targets,” continues Mr. Bundy. “Our goal is to enable researchers to easily characterize the interactions needed to translate in vitro activity to in vivo drug efficacy.”
Agile R100 is the first kinetic characterization platform built with proprietary Field Effect Biosensing (FEB) technology, a breakthrough electrical technique for measuring biomolecular interactions in real time. The easy-to-use, single sample format brings reliable, information-rich data at a price that’s affordable for any lab, providing a cost-effective way to validate hits accurately and increase the efficiency of the drug discovery process.
About Nanomedical Diagnostics
Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive label-free kinetic characterization of biomolecular interactions for accelerated drug discovery. As the world’s leading developer and manufacturer of next-generation graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.
Angela Shue, Nanomedical Diagnostics, Inc., http://www.nanomedicaldiagnostics.com, +1 (858) 255-4330, [email protected]
SOURCE Nanomedical Diagnostics, Inc.